Bayer公司与Cytokinetics公司合作,在日本开发心脏病药物,共支付6.3亿欧元。 Bayer partners with Cytokinetics to develop heart drug aficamten in Japan, paying up to €630 million.

动能学和贝耶尔公司合作在日本开发和销售用于治疗高营养性心血管病的Aficamten (HCM)。 Cytokinetics and Bayer have partnered to develop and sell aficamten in Japan for treating hypertrophic cardiomyopathy (HCM). Cytokinetics 将获得 5000 万欧元的预付款，并有可能再获得高达 5.8 亿欧元的里程碑和特许权使用费。 Cytokinetics will receive €50 million upfront, with potential for up to €580 million more in milestones and royalties. 拜耳将领导阻塞性HCM的第三期试验,而细胞动力学将在日本扩大其试验. Bayer will lead a Phase 3 trial for obstructive HCM, while Cytokinetics will expand its trial in Japan. Aficamten旨在降低中医患者的心脏肌肉萎缩程度。 Aficamten aims to reduce heart muscle contractility in HCM patients.